Royalty Pharma (RPRX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $1.32
- Estimate
- $1.27
- Surprise
- +3.9%
- Revenue (period 2026-06-30)
- $674.1M
- Score at report (before → after)
- 5.2 → 5.4/10
Revenue source: xbrl.
How the report landed
Royalty Pharma (RPRX) beat the $1.27 estimate with diluted EPS of $1.32 — a clear 3.9% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.2/10) to Sell at 5.4/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates RPRX Hold at 5.0/10.
4 of the last 4 quarters beat the estimate; this quarter's +3.9% surprise compares with a +8.9% four-quarter average. Next scheduled report: 2026-11-04.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Analyst target reached - limited upside remaining
- Weak growth
- Negative momentum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $58.60
- Price target
- $63.09
- Stop
- $55.99
- Upside to target
- +7.7%
The stock trades at 31.5× trailing but 10.2× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
RPRX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $33.87B
- P/E (fwd)
- 10.2
- P/E (ttm)
- 31.5
- 52-week range
- $34.63–$64.38
- Off 52-week high
- 9.0%
- RSI (14)
- 37
- Volume vs avg
- 0.89×
- Score today
- 5.0/10